跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2014-000313-31-DE
EUCTR2014-000313-31-DE进行中（未招募）1 期

A double-blind (sponsor unblind), placebo controlled, randomised, parallel group study to evaluate the safety, tolerability and pharmacokinetics of multiple doses of GSK2269557 administered as a dry powder to COPD patients and assessment of dose response using sputum biomarkers. - GSK2269557/PBO, Ph2A, COPD pts, 14 day RD (DPI), Safety&Tolerability, PK, PD, PGx

GlaxoSmithKline Research & Development Ltd0 个研究点目标入组 65 人开始时间: 2014年4月23日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
65
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. The subject has a confirmed and established diagnosis of COPD, as defined by the GOLD guidelines (see Appendix 4).
  • •2. Male or female of non-child bearing potential between 40 and 75 years of age inclusive, at the time of signing the informed consent.
  • •3.The subject has a post-bronchodilator (400 µg salbutamol) FEV1/FVC < 0.7 and FEV1 = 40 % to = 80 % of predicted (Predictions should be according to the European Community of Coal and Steel (ECCS) equations).
  • •4.Subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years (pack years = (cigarettes per day smoked/20) x number of years smoked)).
  • •5.The subject is able to produce > 100 mg of sputum at screening.
  • •6.Body weight = 45 kg and BMI within the range 17 – 32 kg/m2 (inclusive).
  • •7.A female subject is eligible to participate if she is of:
  • •- Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, salpingo-oophrectomy or oophrectomy [for this definition, documented” refers to the outcome of the investigator's/designee’s review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject’s medical records]; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 4.3.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.]
  • •- Has only same-sex partners, when this is her preferred and usual lifestyle.
  • •8.Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 4.3.1. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.
  • •9.Based on averaged QTcF values of triplicate ECGs obtained over a brief recording period (e.g. 5 minutes):
  • •-[QTcF] < 450 msec; or
  • •-QTcF < 480 msec in subjects with Right Bundle Branch Block.
  • •10.Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • •11.A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included if the Investigator [in consultation with the GSK Medical Monitor if required] documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 55
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 10

排除标准

  • •1. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones and cholecystectomy).
  • •2. Subjects who have a past or current medical conditions or diseases that are not well controlled and, which as judged by the Investigator, may affect subject safety or influence the outcome of the study. (Note: Patients with adequately treated and well controlled concurrent medical conditions (e.g. hypertension) ARE permitted to be entered into the study).
  • •3. Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that might, in the opinion of the Investigator, compromise the safety of the subject or affect the interpretation of the results.
  • •4. History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >28 units for males or >21 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
  • •5. History of sensitivity to any of the study medications, or components (such as lactose) thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • •6. A positive test for HIV antibody - tested according to local policies.
  • •7. The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include cannabinoids, amphetamines, barbiturates, cocaine and opiates. The detection of drugs (e.g. benzodiazepines, opiates) taken for a legitimate medical purpose would not necessarily be an exclusion to study participation. The detection of alcohol would not be an exclusion at screening but would need to be negative pre-dose and during the study.
  • •8. A positive pre-study Hepatitis B surface antigen (HBs-Ag) or positive total hepatitis B core antibody (anti-HBc) or positive Hepatitis C antibody result within 3 months.
  • •9. Pregnant females as determined by positive urine hCG test at screening or prior to dosing.
  • •10. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • •11. Lactating females.
  • •12. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • •13. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • •14. Subject has poorly controlled or unstable COPD, defined as the occurrence of any of the following:
  • •- Either: acute worsening of COPD (an exacerbation) that is managed by the subject at home requiring treatment with corticosteroids and/or antibiotics in the 4 weeks prior to the screening visit.
  • •- Or: more than two exacerbations in the previous 2 months prior to the screening visit that required a course of oral corticosteroids and/or antibiotics, or for which the subject was hospitalised.
  • •15. Subject has had a respiratory tract infection treated with antibiotics in the 4 weeks prior to first dose.
  • •16. Subject requires regular treatment with oral corticosteroids or has received oral or parenteral corticosteroids within 4 weeks of screening.

研究者

相似试验

进行中（未招募）
不适用
Double blind (observer Blind) Placebo controlled, clinical-experimental Study of the Phase II for the examination of the local tolerance by Duhring-Chamber-Test as well as open user trial of the product Arnikamed Gelhealthy subjects with normal skin conditions
EUCTR2004-004511-39-DEDr. Theiss Naturwaren GmbH
进行中（未招募）
不适用
``A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patients suffering from premature ejaculation.`` - NDMedDRA version: 9.1Level: LLTClassification code 10036596Term: Premature ejaculationPremature ejaculation
EUCTR2008-005319-16-ITGLAXO SMITHKLINE
撤回
3 期
Placebo-controlled double-blind randomized controlled trial investigating vitamin K supplementation on vascular calcification propensity in vitamin K deficient renal transplant recipientsvascular calcification propensity1004763510003216
NL-OMON49950niversitair Medisch Centrum Groningen40
招募中
不适用
Placebo-gecontroleerde dubbelblinde gerandomiseerde gecontroleerde studie naar vitamine K-suppletie op vasculaire calcificatie-neiging bij niertransplantatiepatiënten met vitamine K-deficiëntieRenal transplant recipients with vitamin K deficiency
NL-OMON23704MCG40
进行中（未招募）
1 期
Vitamin K supplementation after renal transplantatioVitamin K deficiency is highly prevalent among renal transplant recipients, promotes vascular calcification, and is associated with an increased risk of cardiovascular disease. Supplementation of vitamin K among renal transplant recipients is postulated to be associated with improvement of vascular calcification.Study population: Outpatients (age = 18 years), renal transplant recipients with vitamin K deficiency.
EUCTR2019-004906-88-NLniversity Medical Center Groningen40